Treatment of embolic stroke in rats with bortezomib and recombinant human tissue plasminogen activator

Li Zhang; Zheng Gang Zhang; Xianshuang Liu; Ann Hozeska; Nancy Stagliano; William Riordan; Mei Lu; Michael Chopp

doi:10.1160/TH05-07-0477

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2006; 95(01): 166-173
DOI: 10.1160/TH05-07-0477

Animal Models

Schattauer GmbH

Treatment of embolic stroke in rats with bortezomib and recombinant human tissue plasminogen activator

Authors

Li Zhang

¹Department of Neurology
Zheng Gang Zhang

¹Department of Neurology
Xianshuang Liu

¹Department of Neurology
Ann Hozeska

¹Department of Neurology
Nancy Stagliano

²Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts, USA
William Riordan

²Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts, USA
Mei Lu

³Department of Biostatistics and Research Epidemiology Henry Ford Health Sciences Center, Detroit, Michigan, USA
Michael Chopp

¹Department of Neurology

⁴Department of Physics, Oakland University, Rochester, Michigan, USA

Abstract

Summary

Stroke elicits a progressive vascular dysfunction, which contributes to the evolution of brain injury. Thrombolysis with tissue plasminogen activator (tPA) promotes adverse vascular events that limit the therapeutic window of stroke to three hours. Proteasome inhibitors reduce vascular thrombotic and inflammatory events, and consequently protect vascular function. The present study evaluated the neuroprotective effect of bortezomib,a potent and selective inhibitor of the proteasome, alone and in combination with delayed thrombolytic therapy on a rat model of embolic focal cerebral ischemia. Treatment with bortezomib reduces adverse cerebrovascular events including secondary thrombosis,inflammatory responses,and blood brain barrier (BBB) disruption, and hence reduces infarct volume and neurological functional deficit when administrated within 4 h after stroke onset. Combination of bortezomib and tPA extends the thrombolytic window for stroke to6 h, which is associated with the improvement of vascular patency and integrity. Real time RT-PCR of endothelial cells isolated by laser-capture microdissection from brain tissue and Western blot analysis showed that bortezomib upregulates endothelial nitric oxide synthase (eNOS) expression and blocks NF-κB activation. These results demonstrate that bortezomib promotes eNOS dependent vascular protection, and reduces NF-κB dependent vascular disruption, all of which may contribute to neuroprotection after stroke.

Keywords

Animal models - adhesion molecules - plasminogen activators

Full Text

References

References
1 van Gijn J, Dennis MS. Issues and answers in stroke care. Lancet 1998; 352 (Suppl. 03) SIII23-7.
2 del Zoppo G, Ginis I, Hallenbeck JM. et al. Inflammation and stroke: putative role for cytokines, adhesion molecules and iNOS in brain response to ischemia. Brain Pathol 2000; 10: 95-112.
3 Fisher M, Francis R. Altered coagulation in cerebral ischemia. Platelet, thrombin, and plasmin activity. Arch Neurol 1990; 47: 1075-9.
4 Zhang ZG, Chopp M, Goussev A. et al. Cerebral microvascular obstruction by fibrin is associated with upregulation of PAI-1 acutely after onset of focal embolic ischemia in rats. J Neurosci 1999; 19: 10898-907.
5 Chopp M, Zhang ZG. Anti-adhesion molecule and nitric oxide protection strategies in ischemic stroke. Curr Opin Neurol 1996; 09: 68-72.
6 Jean WC, Spellman SR, Nussbaum ES. et al. Reperfusion injury after focal cerebral ischemia: the role of inflammation and the therapeutic horizon. Neurosurgery 1998; 43: 1382-96.
7 Coux O, Tanaka K, Goldberg AL. Structure and functions of the 20S and 26S proteasomes. Annu Rev Biochem 1996; 65: 801-47.
8 Goldberg AL. Functions of the proteasome: the lysis at the end of the tunnel. Science 1995; 268: 522-3.
9 Di Napoli M, Papa F. MLN-519. Millennium/ PAION. Curr Opin Investig Drugs 2003; 04: 333-41.
10 Pye J, Ardeshirpour F, McCain A. et al. Proteasome inhibition ablates activation of NF-kappa B in myocardial reperfusion and reduces reperfusion injury. Am J Physiol Heart Circ Physiol 2003; 284: H919-26.
11 Stangl V, Lorenz M, Meiners S. et al. Long-term upregulation of eNOS and improvement of endothelial function by inhibition of the ubiquitin-proteasome pathway. Faseb J 2004; 18: 272-9.
12 Williams AJ, Hale SL, Moffett JR. et al. Delayed treatment with MLN519 reduces infarction and associated neurologic deficit caused by focal ischemic brain injury in rats via antiinflammatory mechanisms involving nuclear factor-kappaB activation, gliosis, and leukocyte infiltration. J Cereb Blood Flow Metab 2003; 23: 75-87.
13 Zhang RL, Zhang ZG, Chopp M. et al. Thrombolysis with tissue plasminogen activator alters adhesion molecule expression in the ischemic rat brain. Stroke 1999; 30: 624-9.
14 Sumii T, Lo EH. Involvement of matrix metalloproteinase in thrombolysis-associated hemorrhagic transformation after embolic focal ischemia in rats. Stroke 2002; 33: 831-6.
15 Zhang L, Zhang ZG, Zhang RL. et al. Postischemic (6-hour) treatment with recombinant human tissue plasminogen activator and proteasome inhibitor PS-519 reduces infarction in a rat model of embolic focal cerebral ischemia. Stroke 2001; 32: 2926-31.
16 Zivin J, Mazzarella V. Tissue plasminogen activator plus glutamate antagonist improves outcome after embolic stroke. Arch Neurol 1991; 48: 1235-8.
17 Palombella VJ, Conner EM, Fuseler JW. et al. Role of the proteasome and NF-kappaB in streptococcal cell wall-induced polyarthritis. Proc Natl Acad Sci U S A 1998; 95: 15671-6.
18 Adams J, Palombella VJ, Sausville EA. et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 1999; 59: 2615-22.
19 Lightcap ES, McCormack TA, Pien CS. et al. Proteasome inhibition measurements: clinical application. Clin Chem 2000; 46: 673-83.
20 Chen J, Li Y, Wang L. et al. Therapeutic benefit of intracerebral transplantation of bone marrow stromal cells after cerebral ischemia in rats. J Neurol Sci 2001; 189: 49-57.
21 Schallert T, Whishaw IQ. Bilateral cutaneous stimulation of the somatosensory system in hemidecorticate rats. Behav Neurosci 1984; 98: 518-40.
22 Hernandez TD, Schallert T. Seizures and recovery from experimental brain damage. Exp Neurol 1988; 102: 318-24.
23 Swanson RA, Morton MT, Tsao-Wu G. et al. A semiautomated method for measuring brain infarct volume. J Cereb Blood Flow Metab 1990; 10: 290-3.
24 Zhang L, Zhang ZG, Zhang R. et al. Adjuvant treatment with a glycoprotein IIb/IIIa receptor inhibitor increases the therapeutic window for low-dose tissue plasminogen activator administration ina rat model of embolic stroke. Circulation 2003; 107: 2837-43.
25 Mun-Bryce S, Rosenberg GA. Matrix metalloproteinases in cerebrovascular disease. J Cereb Blood Flow Metab 1998; 18: 1163-72.
26 Uchinami H, Yamamoto Y, Kume M. et al. Effect of heat shock preconditioning on NF-kappaB/I-kappaB pathway during I/R injury of the rat liver. Am J Physiol Gastrointest Liver Physiol 2002; 282: G962-71.
27 Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001; 25: 402-8.
28 Zhang ZG, Zhang L, Tsang W. et al. Dynamic platelet accumulation at the site of the occluded middle cerebral artery and in downstream microvessels is associated with loss of microvascular integrity after embolic middle cerebral artery occlusion. Brain Res 2001; 912: 181-94.
29 Stringer HA, van Swieten P, Heijnen HF. et al. Plasminogen activator inhibitor-1 released from activated platelets plays a key role in thrombolysis resistance. Studies with thrombi generated in the Chandler loop. Arterioscler Thromb 1994; 14: 1452-8.
30 Ostrowska JK, Wojtukiewicz MZ, Chabielska E. et al. Proteasome inhibitor prevents experimental arterial thrombosis in renovascular hypertensive rats. Thromb Haemost 2004; 92: 171-7.
31 Kolev K, Skopal J, Simon L. et al. Matrix metalloproteinase-9 expression in post-hypoxic human brain capillary endothelial cells: H2O2 as a trigger and NFkappaB as a signal transducer. Thromb Haemost 2003; 90: 528-37.
32 Elliott PJ, Pien CS, McCormack TA. et al. Proteasome inhibition: A novel mechanism to combat asthma. J Allergy Clin Immunol 1999; 104: 294-300.
33 Justicia C, Panes J, Sole S. et al. Neutrophil infiltration increases matrix metalloproteinase-9 in the ischemic brain after occlusion/reperfusion of the middle cerebral artery in rats. J Cereb Blood Flow Metab 2003; 23: 1430-40.
34 Lo EH, Wang X, Cuzner ML. Extracellular proteolysis in brain injury and inflammation: role for plasminogen activators and matrix metalloproteinases. J Neurosci Res 2002; 69: 1-9.
35 Iadecola C, Pelligrino DA, Moskowitz MA. et al. Nitric oxide synthase inhibition and cerebrovascular regulation. J Cereb Blood Flow Metab 1994; 14: 175-92.
36 Podar K, Shringarpure R, Tai YT. et al. Caveolin-1 is required for vascular endothelial growth factor-triggered multiple myeloma cell migration and is targeted by bortezomib. Cancer Res 2004; 64: 7500-6.
37 Monaco C, Andreakos E, Kiriakidis S. et al. Canonical pathway of nuclear factor kappa B activation selectively regulates proinflammatory and prothrombotic responses in human atherosclerosis. Proc Natl Acad Sci US A 2004; 101: 5634-9.
38 Dechend R, Maass M, Gieffers J. et al. Chlamydia pneumoniae infection of vascular smooth muscle and endothelial cells activates NF-κB and induces tissue factor and PAI-1 expression: a potential link to accelerated arteriosclerosis. Circulation 1999; 100: 1369-73.